These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 16240395)
1. Immunocytochemical identification of carcinomas of unknown primary in serous effusions. Pomjanski N; Grote HJ; Doganay P; Schmiemann V; Buckstegge B; Böcking A Diagn Cytopathol; 2005 Nov; 33(5):309-15. PubMed ID: 16240395 [TBL] [Abstract][Full Text] [Related]
2. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions. Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575 [TBL] [Abstract][Full Text] [Related]
3. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry. Su XY; Li GD; Liu WP; Xie B; Jiang YH Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004 [TBL] [Abstract][Full Text] [Related]
4. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Bassarova AV; Nesland JM; Davidson B Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331 [TBL] [Abstract][Full Text] [Related]
5. Immunocytochemical diagnosis of hepatocellular carcinoma and identification of carcinomas of unknown primary metastatic to the liver on fine-needle aspiration cytologies. Onofre AS; Pomjanski N; Buckstegge B; Böcking A Cancer; 2007 Aug; 111(4):259-68. PubMed ID: 17567831 [TBL] [Abstract][Full Text] [Related]
6. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens. Shield PW; Papadimos DJ; Walsh MD Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220 [TBL] [Abstract][Full Text] [Related]
7. [Differential diagnostic value of B72.3, Ber-EP4 and calretinin in serous effusions]. Li XJ; Pan QJ; Shen GH; Liu XY; Sun YT Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):438-41. PubMed ID: 16188134 [TBL] [Abstract][Full Text] [Related]
8. Malignant effusions: from diagnosis to biology. Davidson B Diagn Cytopathol; 2004 Oct; 31(4):246-54. PubMed ID: 15452897 [TBL] [Abstract][Full Text] [Related]
9. [Immunocytochemical identification of carcinomas of unknown primaries on fine-needle-aspiration-biopsies]. Böcking A; Pomjansky N; Buckstegge B; Onofre A Pathologe; 2009 Dec; 30 Suppl 2():158-60. PubMed ID: 19756620 [TBL] [Abstract][Full Text] [Related]
10. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338 [TBL] [Abstract][Full Text] [Related]
11. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions. Shield PW; Koivurinne K Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095 [TBL] [Abstract][Full Text] [Related]
12. Serous effusions in malignant lymphomas: a review. Das DK Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559 [TBL] [Abstract][Full Text] [Related]
13. Use of monoclonal antibody B72.3 as a marker of metastatic carcinoma cells in neoplastic effusions. Betta PG; Pavesi M; Pastormerlo M; Tallarida F; Bellingeri D; Bocca R Pathologica; 1991; 83(1083):99-104. PubMed ID: 1866206 [TBL] [Abstract][Full Text] [Related]
14. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis. Onofre FB; Onofre AS; Pomjanski N; Buckstegge B; Grote HJ; Böcking A Cancer; 2008 Jun; 114(3):204-15. PubMed ID: 18306350 [TBL] [Abstract][Full Text] [Related]
15. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Davidson B; Baekelandt M; Shih IeM Diagn Cytopathol; 2007 Dec; 35(12):756-60. PubMed ID: 18008338 [TBL] [Abstract][Full Text] [Related]
16. Usefulness of Claudin 4 in the cytological diagnosis of serosal effusions. Lonardi S; Manera C; Marucci R; Santoro A; Lorenzi L; Facchetti F Diagn Cytopathol; 2011 May; 39(5):313-7. PubMed ID: 21488172 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions. Slipicevic A; Øy GF; Askildt IC; Holth A; Hellesylt E; Flørenes VA; Davidson B Hum Pathol; 2009 Apr; 40(4):527-37. PubMed ID: 19121847 [TBL] [Abstract][Full Text] [Related]
18. Utility of thyroid transcription factor-1 and CDX-2 in determining the primary site of metastatic adenocarcinomas in serous effusions. Kim JH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C Acta Cytol; 2010; 54(3):277-82. PubMed ID: 20518411 [TBL] [Abstract][Full Text] [Related]
19. Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach. DeYoung BR; Wick MR Semin Diagn Pathol; 2000 Aug; 17(3):184-93. PubMed ID: 10968704 [TBL] [Abstract][Full Text] [Related]
20. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears. Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]